Abstract
Epileptic encephalopathies are severe often intractable seizure disorders where epileptiform abnormalities contribute to a progressive disturbance in brain function. Often, epileptic encephalopathies start in childhood and are accompanied by developmental delay and various neurological and non-neurological comorbidities. In recent years, this concept has become virtually synonymous with a group of severe childhood epilepsies including West syndrome, Lennox-Gastaut syndrome, Dravet syndrome, and several other severe childhood epilepsies for which genetic factors are increasingly recognized. In the last 5 years, the field has seen a virtual explosion of gene discovery, raising the number of bona fide genes and possible candidate genes for epileptic encephalopathies to more than 70 genes, explaining 20-25% of all cases with severe early-onset epilepsies that had otherwise no identifiable causes. This review will focus on the phenotypic variability as a characteristic aspect of genetic epilepsies. For many genetic epilepsies, the phenotypic presentation can be broad, even in patients with identical genetic alterations. Furthermore, patients with different genetic etiologies can have seemingly similar clinical presentations, such as in Dravet syndrome. While most patients carry mutations in SCN1A, similar phenotypes can be seen in patients with mutations in PCDH19, CHD2, SCN8A, or in rare cases GABRA1 and STXBP1. In addition to the genotypic and phenotypic heterogeneity, both benign phenotypes and severe encephalopathies have been recognized in an increasing number of genetic epilepsies, raising the question whether these conditions represent a fluid continuum or distinct entities.
References
1.
Archer HL, Evans J, Edwards S, Colley J, Newbury-Ecob R, et al: CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. J Med Genet 43:729-734 (2006).
2.
Banerjee PN1, Filippi D, Allen Hauser W: The descriptive epidemiology of epilepsy - a review. Epilepsy Res 85:31-45 (2009).
3.
Barcia G, Fleming MR, Deligniere A, Gazula VR, Brown MR, et al: De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet 44:1255-1259 (2012).
4.
Bayat A, Hjalgrim H, Møller RS: The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22,000: a population-based study from 2004 to 2009. Epilepsia 56:e36-39 (2015).
5.
Berkovic SF, Heron SE, Giordano L, Marini C, Guerrini R, et al: Benign familial neonatal-infantile seizures: characterization of a new sodium channelopathy. Ann Neurol 55:550-557 (2004).
6.
Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, et al: A potassium channel mutation in neonatal human epilepsy. Science 279:403-406 (1998).
7.
Carvill GL, Heavin SB, Yendle SC, McMahon JM, OʼRoak BJ, et al: Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet 45:825-830 (2013).
8.
Carvill GL, Weckhuysen S, McMahon JM, Hartmann C, Møller RS, et al: GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. Neurology 82:1245-1253 (2014).
9.
Carvill GL, McMahon JM, Schneider A, Zemel M, Myers CT, et al: Mutations in the GABA transporter SLC6A1 cause epilepsy with myoclonic-atonic seizures. Am J Hum Genet 96:808-815 (2015).
10.
Chen Y, Lu J, Pan H, Zhang Y, Wu H, et al: Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol 54:239-243 (2003).
11.
Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P: De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 68:1327-1332 (2001).
12.
Claes L, Ceulemans B, Audenaert D, Smets K, Löfgren A, et al: De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy. Hum Mutat 21:615-621 (2003).
13.
Cossette P, Liu L, Brisebois K, Dong H, Lortie A, et al: Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat Genet 31:184-189 (2002).
14.
De Vivo DC, Trifiletti RR, Jacobson RI, Ronen GM, Behmand RA, Harik SI: Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 325:703-709 (1991).
15.
Dibbens LM, Feng HJ, Richards MC, Harkin LA, Hodgson BL, et al: GABRD encoding a protein for extra- or peri-synaptic GABAA receptors is a susceptibility locus for generalized epilepsies. Hum Mol Genet 13:1315-1319 (2004).
16.
Epi4K Consortium, Epilepsy Phenome/Genome Project, Allen AS, Berkovic SF, Cossette P, et al: De novo mutations in epileptic encephalopathies. Nature 501:217-221 (2013).
17.
Escayg A, Goldin AL: Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia 51:1650-1658 (2010).
18.
Escayg A, MacDonald BT, Meisler MH, Baulac S, Huberfeld G, et al: Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet 24:343-345 (2000).
19.
EuroEPINOMICS-RES Consortium; Epilepsy Phenome/Genome Project; Epi4K Consortium: De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet 95:360-370 (2014).
20.
Falace A, Filipello F, La Padula V, Vanni N, Madia F, et al: TBC1D24, an ARF6-interacting protein, is mutated in familial infantile myoclonic epilepsy. Am J Hum Genet 87:365-370 (2010).
21.
Feenstra B, Pasternak B, Geller F, Carstensen L, Wang T, et al: Common variants associated with general and MMR vaccine-related febrile seizures. Nat Genet 46:1274-1282 (2014).
22.
Gardella E, Becker F, Møller RS, Schubert J, Lemke JR, et al: Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation. Ann Neurol 79:428-436 (2016).
23.
Goldberg-Stern H, Aharoni S, Afawi Z, Bennett O, Appenzeller S, et al: Broad phenotypic heterogeneity due to a novel SCN1A mutation in a family with genetic epilepsy with febrile seizures plus. J Child Neurol 29:221-226 (2014).
24.
Guerrini R: Epilepsy in children. Lancet 367:499-524 (2006).
25.
Guerrini R, Cellini E, Mei D, Metitieri T, Petrelli C, et al: Variable epilepsy phenotypes associated with a familial intragenic deletion of the SCN1A gene. Epilepsia 51:2474-2477 (2010).
26.
Harkin LA, McMahon JM, Iona X, Dibbens L, Pelekanos JT, et al: The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 130:843-852 (2007).
27.
Haug K, Warnstedt M, Alekov AK, Sander T, Ramírez A, et al: Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nat Genet 33:527-532 (2003).
28.
Helbig I: Genetic causes of generalized epilepsies. Semin Neurol 35:288-292 (2015).
29.
Heron SE, Crossland KM, Andermann E, Phillips HA, Hall AJ, et al: Sodium-channel defects in benign familial neonatal-infantile seizures. Lancet 360:851-852 (2002).
30.
Heron SE, Smith KR, Bahlo M, Nobili L, Kahana E, et al: Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 44:1188-1190 (2012).
31.
Howell KB, McMahon JM, Carvill GL, Tambunan D, Mackay MT, et al: SCN2A encephalopathy: a major cause of epilepsy of infancy with migrating focal seizures. Neurology 85:958-966 (2015).
32.
International League Against Epilepsy Consortium on Complex Epilepsies: Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. Lancet Neurol 13:893-903 (2014).
33.
Kalscheuer VM, Tao J, Donnelly A, Hollway G, Schwinger E, et al: Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation. Am J Hum Genet 72:1401-1411 (2003).
34.
Kasperaviciute D, Catarino CB, Matarin M, Leu C, Novy J, et al: Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A. Brain 136:3140-3150 (2013).
35.
Meng H, Xu HQ, Yu L, Lin GW, He N, et al: The SCN1A mutation database: updating information and analysis of the relationships among genotype, functional alteration, and phenotype. Hum Mutat 36:573-580 (2015).
36.
Miller IO, Sotero de Menezes MA: SCN1A-related seizure disorders, in Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, et al. (eds): GeneReviews(R) (University of Washington, Seattle 1993).
37.
Møller RS, Heron SE, Larsen LH, Lim CX, Ricos MG, et al: Mutations in KCNT1 cause a spectrum of focal epilepsies. Epilepsia 56:e114-120 (2015).
38.
Mullen SA, Suls A, De Jonghe P, Berkovic SF, Scheffer IE: Absence epilepsies with widely variable onset are a key feature of familial GLUT1 deficiency. Neurology 75:432-440 (2010).
39.
Nabbout R, Chemaly N, Chipaux M, Barcia G, Bouis C, et al: Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis 8:176 (2013).
40.
Nakamura K, Kato M, Osaka H, Yamashita S, Nakagawa E, et al: Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome. Neurology 81:992-998 (2013).
41.
Ogiwara I, Nakayama T, Yamagata T, Ohtani H, Mazaki E, et al: A homozygous mutation of voltage-gated sodium channel β1 gene SCN1B in a patient with Dravet syndrome. Epilepsia 53:e200-203 (2012).
42.
Pal D, Helbig I: Commentary: pathogenic EFHC1 mutations are tolerated in healthy individuals dependent on reported ancestry. Epilepsia 56:195-196 (2015).
43.
Patino GA, Claes LR, Lopez-Santiago LF, Slat EA, Dondeti RS, et al: A functional null mutation of SCN1B in a patient with Dravet syndrome. J Neurosci 29:10764-10778 (2009).
44.
Reutlinger C, Helbig I, Gawelczyk B, Subero JI, Tönnies H, et al: Deletions in 16p13 including GRIN2A in patients with intellectual disability, various dysmorphic features, and seizure disorders of the rolandic region. Epilepsia 51:1870-1873 (2010).
45.
Richards S, Aziz N, Bale S, Bick D, Das S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405-424 (2015).
46.
Roll P, Rudolf G, Pereira S, Royer B, Scheffer IE, et al: SRPX2 mutations in disorders of language cortex and cognition. Hum Mol Genet 15:1195-1207 (2006).
47.
Saitsu H, Kato M, Mizuguchi T, Hamada K, Osaka H, et al: De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat Genet 40:782-788 (2008).
48.
Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, et al: A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 18:25-29 (1998).
49.
Singh NA, Pappas C, Dahle EJ, Claes LR, Pruess TH, et al: A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. PLoS Genet 5:e1000649 (2009).
50.
Stamberger H, Nikanorova M, Willemsen MH, Accorsi P, Angriman M, et al: STXBP1 encephalopathy: a neurodevelopmental disorder including epilepsy. Neurology 86:954-962 (2016).
51.
Steinlein OK: Genetic mechanisms that underlie epilepsy. Nat Rev Neurosci 5:400-408 (2004).
52.
Strømme P, Mangelsdorf ME, Shaw MA, Lower KM, Lewis SM, et al: Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat Genet 30:441-445 (2002).
53.
Subaran RL, Conte JM, Stewart WC, Greenberg DA: Pathogenic EFHC1 mutations are tolerated in healthy individuals dependent on reported ancestry. Epilepsia 56:188-194 (2015).
54.
Suls A, Mullen SA, Weber YG, Verhaert K, Ceulemans B, et al: Early-onset absence epilepsy caused by mutations in the glucose transporter GLUT1. Ann Neurol 66:415-419 (2009).
55.
Suls A, Jaehn JA, Kecskés A, Weber Y, Weckhuysen S, et al: De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome. Am J Hum Genet 93:967-975 (2013).
56.
Suzuki T, Delgado-Escueta AV, Aguan K, Alonso ME, Shi J, et al: Mutations in EFHC1 cause juvenile myoclonic epilepsy. Nat Genet 36:842-849 (2004).
57.
Veeramah KR, OʼBrien JE, Meisler MH, Cheng X, Dib-Hajj SD, et al: De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. Am J Hum Genet 90:502-510 (2012).
58.
Weaving LS, Christodoulou J, Williamson SL, Friend KL, McKenzie OL, et al: Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am J Hum Genet 75:1079-1093 (2004).
59.
Weckhuysen S, Mandelstam S, Suls A, Audenaert D, Deconinck T, et al: KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy. Ann Neurol 71:15-25 (2012).
60.
Weckhuysen S, Ivanovic V, Hendrickx R, Van Coster R, Hjalgrim H, et al: Extending the KCNQ2 encephalopathy spectrum: clinical and neuroimaging findings in 17 patients. Neurology 81:1697-1703 (2013).
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
